Tedco Logo Template png 975×485

$600,000 invested into 3 new ventures and $1.6Million awarded to 12 project grants

COLUMBIA, Md. (March 23, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent round of funding through the Maryland Innovation Initiative (MII).

Established in 2012, the MII program was created as a partnership between the State of Maryland and five Maryland academic research institutions: Johns Hopkins University; Morgan State University; University of Maryland, Baltimore; University of Maryland, Baltimore County; and University of Maryland, College Park. The program’s mission is to accelerate and support the commercialization of promising technologies from bench to market through investments in innovation, entrepreneurship and venture creation.

Li SunGift Luncheon 01232023 SC 3754 1920x1080

When husband and wife Zairen Sun Ph.D. ’98 and Beibei Li Ph.D. ’98 arrived in College Park from China in 1992, they had little understanding of their new country or its traditions or practices. What they did have was a mentor at the University of Maryland who knew what it was like to be an immigrant to the U.S.—and who could empathize with the process of adjusting to a very different way of doing things.

 

Emergent Logo
  • NARCAN® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening access
  • Expected over-the-counter availability is anticipated by late summer of this year

GAITHERSBURG, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose. This decision comes at a time when approximately every eight minutes, a person dies from an opioid overdose and research shows the epidemic is escalating in the U.S. with the rise in synthetic opioids. By offering NARCAN® Nasal Spray as an OTC treatment, anyone will be able to access it without a prescription, which is an important step in the fight to reduce the number of opioid overdose deaths occurring each day.

SlubrisBio Logo

MARCH 28, 2023 - GAITHERSBURG, Md., (BUSINESS WIRE) -- Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd. The investment will be used to advance and accelerate lead candidate JK07, including the planned initiation of the first Phase 2 study in HFrEF, the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction (HFpEF), and the launch of the Company’s first neurology clinical trial with JK07. The financing will also support the ongoing Phase 1/2 trial of JK08 in solid tumors and advance JK06, a pre-clinical biparatopic antibody-drug conjugate, into an initial Phase 1/2 study.

MIMETAS logo V2

Leiden, the Netherlands , March 28, 2023 / B3C newswire / -- MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company. The partnership comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies.

Vishal and Rich

Ready to explore the frontiers of cancer therapeutics? Discover how AUM Biosciences, with a key presence in Montgomery County, Maryland, in the BioHealth Capital Region, is revolutionizing the development of innovative oncology medicines and transforming the fight against cancer resistance. Join us on this episode of BioTalk with Rich Bendis as we chat with Vishal Doshi, Chairman & CEO of AUM Biosciences, a visionary leader in the biotech industry. Tune in to the conversation that's sparking new hope in the battle against cancer.

Listen now via your favorite podcast platforms: Apple - https://apple.co/42LvH4A Google - https://bit.ly/40yTOBC Spotify - https://spoti.fi/40F2NkV Amazon Music - https://amzn.to/40hFz4L TuneIn - https://bit.ly/42Gpfff YouTube - https://bit.ly/3TMIuji

Macrogenics

ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration's (FDA) approval of Incyte's Biologics License Application (BLA) for ZYNYZ™ (retifanlimab-dlwr), the Company will receive a $15 million milestone payment from Incyte. ZYNYZ, a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), was previously developed by MacroGenics and licensed to Incyte pursuant to an exclusive global collaboration and license agreement in October 2017.

BioBuzz FITCI Partnership

MARYLAND, March 23, 2023 — BioBuzz, the media outlet of Workforce Genetics, and the Frederick Innovative Technology Center, Inc. (FITCI) have announced a strategic partnership to fuel industry growth in the BioHealth Capital Region and growth for both parties.

FITCI CEO Kathie Callahan Brady says she is excited to move forward. “We both focus on the biotech space, but the perspective is different. It is exactly the type of collaboration we want to infuse into our new EDGE@321 entrepreneurial innovation center opening later this year, bridging competencies and markets to strengthen the whole community.”

Image: https://biobuzz.io

Ideas and innovations 2021 08 26 23 02 46 utc

There has been a smoldering fire on the geopolitical stage that, if we continue to ignore, we risk allowing it to spread and burn its surrounding environment. I’m referring to the convergence of multiple technology revolutions with the high-stakes competition between the United States and a rising authoritarian competitor in China.

 

9b3e8621 8573 8133 367b a4893b5ac33d

Event provides forum for researchers to learn more about ARPA-H’s Open Broad Agency Announcement

ARPA-H has opened its first Agency-wide Open BAA, seeking funding proposals for research aiming to improve health outcomes across patient populations, communities, diseases, and health conditions.

On April 4, ARPA-H will host a Proposers’ Day for interested parties to learn more about the application process for the Open BAA and ask questions. Register for the event. (Registration closes 5 p.m. ET on Monday, March 3)

Image001

 

MARYLAND, March 23, 2023 — BioBuzz, the media outlet of Workforce Genetics, and the Frederick Innovative Technology Center, Inc. (FITCI) have announced a strategic partnership to fuel industry growth in the BioHealth Capital Region and growth for both parties.

FITCI CEO Kathie Callahan Brady says she is excited to move forward. “We both focus on the biotech space, but the perspective is different. It is exactly the type of collaboration we want to infuse into our new EDGE@321 entrepreneurial innovation center opening later this year, bridging competencies and markets to strengthen the whole community.”

Image001

Riley-Brown will succeed Kurt Newman, M.D., who has served in role for over 11 years

March 23, 2023

The Children’s National Board of Directors announced today that Michelle Riley-Brown, MHA, FACHE, has been named as the new president and chief executive officer (CEO) of Children’s National Hospital. On July 1, Riley-Brown will succeed Kurt Newman, M.D., who is retiring after 11 years as president and CEO.

Riley-Brown is an accomplished executive with over 20 years of experience leading and supporting children’s healthcare. She is currently an executive vice president at Texas Children’s Hospital at the Texas Medical Center in Houston, where she serves concurrently as the president of two hospitals in the system while leading the construction and staffing of a third. She also leads system-level operations, strategic planning, physician practice acquisition, quality performance, clinical operations, fund development, marketing, brand management and public relations for the nation’s largest pediatric and women’s healthcare organization.

Vishal Doshi is the founder and CEO of AUM Biosciences.
Photo: AUM Biosciences.

Whenever someone asks about dreams, there is an underlying expectation that it is something that springs up on you at a nascent age, like an epiphany where you’ve realised your life’s calling. But that is not always the case. For me, founding a global biotechnology company was not an overnight phenomenon, but a dream that gradually materialised as I started helping at my family’s pharmacy when I was eight.

Image: Vishal Doshi is the founder and CEO of AUM Biosciences. Photo: AUM Biosciences.

Sally Allain 200x300

At Johnson & Johnson Innovation – JLABS, part of our mission is to bring big company benefits to entrepreneurs and startups, along with our network. We also know that networks really do matter when it comes to access to capital.

In leaning into our mission, on March 9th, we brought together more than 30 startup companies and 30 investors from across the US and Canada to JLABS @ Washington, DC for our second annual Johnson & Johnson Innovation – JLABS East North America Investor & Partnering Event.

 

C8c8b19baa99336b 350x0 85 files Workshop and trainings Mimetas lab zw 2020 05

Leiden, March 3, 2023 – MIMETAS has achieved major milestones in its partnership with Roche, developing models for Inflammatory Bowel Disease (IBD) and Hepatitis B Virus infections (HBV).

In July 2021, MIMETAS and Roche entered a risk-sharing collaboration to develop human disease models for the characterization of novel compounds in Inflammatory Bowel Disease (IBD) and Hepatitis B virus infections (HBV). You can find the original press release here.

Image: https://www.mimetas.com